Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

3.70USD
4:00pm EDT
Change (% chg)

$-0.10 (-2.63%)
Prev Close
$3.80
Open
$3.85
Day's High
$3.85
Day's Low
$3.65
Volume
47,290
Avg. Vol
68,982
52-wk High
$9.05
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Perceptive Advisors reports 5.57 pct stake in Adamis Pharma
Monday, 24 Apr 2017 09:21am EDT 

April 24 (Reuters) - Adamis Pharmaceuticals Corp ::Perceptive Advisors LLC reports 5.57 percent passive stake in Adamis Pharmaceuticals Corp as of April 21 - SEC filing.  Full Article

Adamis Pharmaceuticals announces pricing of public offering of common stock
Friday, 21 Apr 2017 09:13am EDT 

April 21 (Reuters) - Adamis Pharmaceuticals Corp :Adamis Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 4.29 million common shares priced at $3.50per share.Adamis Pharmaceuticals Corp - Offering is expected to close on April 26, 2017.  Full Article

Adamis Pharmaceuticals announces proposed public offering of common stock
Thursday, 20 Apr 2017 04:01pm EDT 

April 20 (Reuters) - Adamis Pharmaceuticals Corp -:Adamis Pharmaceuticals announces proposed public offering of common stock.Adamis Pharmaceuticals -intends to use net proceeds for general corporate purposes, which may includeexpenditures relating to research, among others.  Full Article

Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals
Tuesday, 9 Aug 2016 03:29pm EDT 

Adamis Pharmaceuticals Corp : Sabby Management, LLC reports 7.73 pct passive stake in Adamis Pharmaceuticals as of August 3, 2016 - SEC Filing Source - http://bit.ly/2aJYpKi Further company coverage: [ADMP.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

CVI Investments reports 5.5 pct passive stake in Adamis Pharmaceuticals
Monday, 8 Aug 2016 01:30pm EDT 

:CVI Investments Inc reports a passive stake of 5.5 percent in Adamis Pharmaceuticals Corp as of July 29, 2016 - SEC Filing.  Full Article

Adamis Pharmaceuticals announces $11.1 mln offering
Friday, 29 Jul 2016 08:45am EDT 

Adamis Pharmaceuticals Corp : Adamis Pharmaceuticals announces $11.1 million registered direct offering . Estimates that net offering proceeds, after deducting placement agent fees, will be approximately $10.3 million .Adamis Pharmaceuticals Corp says offering was priced at $3.095 per unit.  Full Article

Adamis Pharmaceuticals- private placement of about $5 mln
Tuesday, 12 Jul 2016 09:00am EDT 

Adamis Pharmaceuticals Corp : Adamis Pharmaceuticals announces private placement . Says received gross cash proceeds of approximately $5 million .Says issued 1.7 million shares of series A-2 convertible preferred stock to a small number of institutional investors.  Full Article

Adamis receives response letter from FDA for its epinephrine syringe
Monday, 6 Jun 2016 06:55am EDT 

Adamis Pharmaceuticals : FDA indicated that in order to support approval of product, company must expand its human factors study . Believes that it can finalize study protocols with FDA and complete additional testing within a "relatively short period of time" . Believes that it can submit data back to FDA sometime in second half of 2016 .Receives complete response letter from FDA for its epinephrine pre-filled syringe NDA.  Full Article

Adamis Pharmaceuticals Completes Acquisition of US Compounding
Tuesday, 12 Apr 2016 06:45am EDT 

Adamis Pharmaceuticals Corporation:completed its previously announced acquisition (the "Acquisition") of US Compounding, Inc. ("USC").Upon the closing of this transaction, USC has become a wholly-owned subsidiary of Adamis.  Full Article

Adamis Pharmaceuticals announces NDA Resubmission of Epinephrine Pre-Filled Syringe Application to FDA
Monday, 7 Dec 2015 09:03am EST 

Adamis Pharmaceuticals Corporation:Announced the resubmission of the Company's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis.Resubmission is intended to address the issues raised by the FDA in the agency's March 2015 Complete Response Letter (CRL).  Full Article

More From Around the Web

BRIEF-Adamis Pharmaceuticals announces closing of public offering

* Adamis Pharmaceuticals announces closing of public offering of common stock and exercise of over-allotment option in full Source text for Eikon: Further company coverage: